This retrospective study assesses risk stratification and clinical outcomes in early luminal-type breast cancer based on Ki-67 and progesterone receptor levels.
Key Points
The aim is to develop a stratification framework and risk score to predict outcomes for hormone receptor-positive early breast cancer patients after chemotherapy.
Conducted a retrospective analysis of two cohorts totaling 3780 patients.
Categorized patients into four risk groups based on PR and Ki-67 levels.
Developed a quantitative risk score using clinical and pathological parameters.
Evaluated the impact of adjuvant chemotherapy on disease-free survival.
The PR10/Ki20 model showed consistent prognostic performance across both cohorts.
High-risk patients had poorer disease-free and overall survival compared to low-risk patients.
Adjuvant chemotherapy improved disease-free survival for high-risk patients but not for low-risk patients.
The quantitative risk score effectively differentiated between high- and low-risk groups based on survival outcomes.